Daniel E. Stange

The paper identifies UBP1 loss as a driver of oxaliplatin resistance in gastric cancer by revealing a compensatory reliance on translation initiation, which can be targeted with 4EGI.

This study develops an ex vivo drug sensitivity testing platform for rare solid tumors and finds that high in vitro sensitivity correlates with clinical benefit and progression-free survival.

The paper investigates tumor clone dynamics in gastro-esophageal cancer organoids after neoadjuvant chemotherapy, finding that NFκB signaling downregulation contributes to non-genetic transcriptional reprogramming.

This study identifies xCT regulation pathways in colon cancer using patient-specific models and reveals potential therapeutic targets for chemotherapy resistance.